Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx Corp has demonstrated solid growth prospects with a reported third-quarter revenue of $21.5 million, reflecting a 5% increase year-over-year, driven by the continued adoption of its Zephyr Valve for severe emphysema treatment. The company's gross margin remains strong at 75%, while the narrowing of its net loss to $14.0 million indicates improved operational efficiency amidst disciplined cost management. Furthermore, international expansion contributed to a 15% sales increase, signaling robust momentum that complements the company’s strategic initiatives in clinical and commercial developments, positioning it favorably for sustained growth in upcoming periods.

Pulmonx Corp reported preliminary Q3 revenue of approximately $21.5 million, indicating a sequential decline from Q2's revenue of $23.9 million, which highlights a slowing growth trajectory and led to a lowered annual guidance to $90 million–$92 million. The recent management transition, with the return of Glen French as CEO and the appointment of Derrick Sung as COO/CFO, raises concerns regarding the company's operational stability and execution risk moving forward. Additionally, pressures on top-line growth and a decrease in gross margins, which were 72% in Q2, further compound the challenges Pulmonx faces in maintaining financial performance.